BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

AN2 Therapeutics (ANTX)AN2 TherapeuticsConference / presentation

MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 17, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate

Related news

ANTXAN2 Therapeutics2025-11-06 22:03 EST

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

AVIRAtea2026-01-06 12:00 EST

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

ENTAEnanta Pharmaceuticals2026-01-05 12:00 EST

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

AVIRAtea2025-11-19 12:00 EST

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

ASMBAssembly Biosciences2026-05-11 12:00 EST

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

MBRXMoleculin Biotech, Inc.2026-03-17 13:05 EST

Moleculin to Present at 38th Annual ROTH Conference

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning infectious disease and hematology. Epetraborole in M. abscessus Epetraborole is an oral investigational therapy being studied in an investigator-initiated Phase 2 trial for *Mycobacterium...

Recent company news

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-05-07 20:01 EST

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

ANTXAN2 Therapeutics2026-03-31 11:00 EST

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

Stock data

Close
6.08 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States